Search Results
Results 401 - 450 of 1362
< 4 5 6 7 8 9 10 11 12 13 14 >
Chitsike Rufaro - - 2011
Objective: To determine whether dosage adjustment of enoxaparin during pregnancy, to maintain a peak anti-Xa of 1.0 to 1.2 U/mL, is safe for women with mechanical prosthetic heart valves (MPHV). Design: A prospective observational study. Setting: This study was performed at Charlotte Maxeke Johannesburg Academic Hospital from 2007 to 2009. ...
Brown Haywood L - - 2010
Venous thromboembolism is a leading cause for maternal mortality. Because of the increase risk for thromboembolism in pregnancy and the postpartum period, the clinician must be on high alert for the signs and symptoms and use appropriate diagnostics in a timely manner so that prompt anticoagulation therapy can be initiated. ...
Hussein Ayman S - - 2010
Pregnancy is a hypercoagulable state with increased tendency for thrombus formation, a condition that is increased when combined with acquired or inherited risk factors that lead to thrombophilia. Among the inherited risk factors is Factor V Leiden mutation, an autosomal dominant trait with reduced penetrance. The mutation seems to be ...
Davis Sarah M - - 2010
Venous thrombosis and embolism (VTE) is one of the most common, serious complications associated with pregnancy, and now ranks as a leading cause of maternal morbidity and mortality in developed countries. Information regarding the association of VTE with acquired and heritable thrombophilias has greatly expanded in the last 20 years, ...
Ziakas Panayiotis D - - 2010
OBJECTIVE: To estimate the effect of combined heparin and aspirin compared with aspirin monotherapy in pregnant women with antiphospholipid syndrome and recurrent pregnancy loss. DATA SOURCES: We searched the PubMed database up to December 2009 for English-language studies using the key words "aspirin AND (heparin OR low molecular weight heparin), ...
De Paschale Massimo - - 2010
Since 1998, Italian law requires serological screening for toxoplasmosis by the thirteenth week of pregnancy, and seronegative women should undergo further checks every 30 - 40 days until delivery (a total of 5 - 7 screenings). This is an improvement of the previous law which foresaw three free tests (one ...
- - 2010
Inherited thrombophilias are associated with an increased risk of venous thromboembolism and also have been linked to adverse outcomes in pregnancy. However, there is limited evidence to guide screening for and management of these conditions in pregnancy. The purpose of this document is to review common thrombophilias and their association ...
Jurus D - - 2010
Combined with the enlarging uterus compressing the venous system of the pelvis and the vessel trauma incurred in delivery, an increase in clotting factor production in pregnancy predisposes the gravid patient to the peril of thromboembolism. When a patient has an inherited thrombophilia and becomes pregnant, this combination of risk ...
RaĊ£iu A - - 2010
to determine whether a negative single complete ultrasound (US) of the lower limbs veins is a safe and accurate diagnostic method to rule out deep venous thrombosis (DVT) in pregnancy. We performed a prospective study on 87 consecutive pregnant women with clinical suspicion of DVT in "Dr. D. Popescu" Maternity, ...
Clark Peter - - 2010
To assess whether treatment with enoxaparin and low-dose aspirin, along with intensive pregnancy surveillance, reduces rate of pregnancy loss compared with intensive pregnancy surveillance alone in women with history of 2 or more consecutive previous pregnancy losses, a parallel group, multicenter, randomized controlled trial was performed in the United Kingdom ...
Naru T - - 2010
This retrospective review of hospital records analysed pregnancy outcome with 2 different treatments for women with recurrent miscarriage diagnosed with antiphospholipid syndrome in the index pregnancy. Of 64 women, 29 had received aspirin and 35 aspirin plus heparin. Pregnancy-induced hypertension, prematurity, intrauterine growth restriction and neonatal death were considered as ...
Ozornek Hakan - - 2010
PROBLEM: To compare the prevalence of 112T>C point mutations among women experiencing RPL with fertile control women. METHOD OF STUDY: Buccal swabs were obtained from 232 individuals: 136 with a history of >or=2 abortions, 37 with at least 2 live births and 59 with a history of deep vein thrombosis ...
Chauleur Celine - - 2010
Management of pregnant women at risk for venous thromboembolism (VTE) remains complex. Guidelines do not definitively fix optimal strategies due to limited trial data. Our objective was to build an easy-to-use tool allowing individualised, risk-adapted prophylaxis. A Delphi exercise was conducted to collect 19 French experts' opinions on pregnancy-related VTE. ...
Galanaud J P - - 2010
BACKGROUND: Half of all venous thromboembolism (VTE) cases during pregnancy are associated with a maternal thrombophilia. The influence of paternal genotype on the placenta and in the genesis of VTE has not been described. OBJECTIVES: To determine if the maternal and paternal Ser219Gly dimorphism of the endothelial protein C receptor ...
Abu-Skeen Ibrahim A - - 2010
OBJECTIVE: To investigate the presence of factor V Leiden (FVL), and prothrombin gene mutations (PRT), protein C and protein S in pregnant women with a previous history of thromboembolism, and evaluate their impact on maternal and fetal outcomes. METHODS: This study was carried out at Ain Shams University Hospital, Cairo, ...
Tang Sung-Chun - - 2010
Pregnancy and the puerperium have been recognized to increase the risk of stroke, particularly from late pregnancy and through the puerperium. The reported incidences of stroke during pregnancy and the puerperium varied widely, ranging from 5 to 67 per 100,000 deliveries or pregnancies. Important causes of stroke during pregnancy and ...
James Andra H - - 2010
Pregnancy increases the risk of thrombosis three-fold to four-fold. The main reason for the increased risk is hypercoagulability, which has likely evolved to protect women against the bleeding challenges associated with miscarriage and childbirth. The hypercoagulability of pregnancy is present as early as the first trimester and so is the ...
Chan W-S - - 2010
SUMMARY BACKGROUND: The role of D-dimer in excluding deep vein thrombosis (DVT) in pregnancy is currently uncertain. We hypothesized that the specificity of sensitive D-dimer assays could be improved without compromising sensitivity by using higher D-dimer cut-off values. OBJECTIVE: To determine the test characteristics of two rapid enzyme-linked immunosorbent assays ...
Mehndiratta Sumit - - 2010
Fetal warfarin syndrome (warfarin embryopathy) is a consequence of maternal ingestion of warfarin during pregnancy. Warfarin fetotoxicity comprises wide range of manifestations including dysmorphology in neonate with characteristic classical features of nasal hypoplasia and stippling of epiphyses. Here we present a case of a neonate whose mother was on unsupervised ...
Sabadell Jordi - - 2010
OBJECTIVE: To describe the outcome of pregnancy in women with inherited antithrombin (AT) deficiency. STUDY DESIGN: A descriptive retrospective study was performed. Medical records were reviewed in order to collect data about maternal thrombotic complications and pregnancy outcomes. All women with known inherited AT deficiency and at least one pregnancy ...
Andersen Anita Sylvest - - 2010
OBJECTIVE: To evaluate the safety of individually dosed low molecular weight heparin (LMWH) for prophylaxis and treatment of thromboembolic complications in pregnancy. DESIGN: Cohort study with a chronologic register-based control group. SETTING: Department of Obstetrics and Gynecology, Hillerød Hospital, Denmark. POPULATION: All 166 women treated with LMWH in pregnancy between ...
Kovac Mirjana - - 2010
OBJECTIVE: D-dimer testing has an important role in the exclusion of acute venous thromboembolism (VTE) in the nonpregnant population. Establishing D-dimers role in the diagnosis of VTE in pregnancy is hampered because of the substantial increase of D-dimer throughout gestational age. STUDY DESIGN: In a prospective study we followed 89 ...
Kovac M - - 2010
Existing data regarding the prevalence of thrombophilia in women with pregnancy complications are conflicting. To investigate the relationship between pregnancy-associated complications and the presence of thrombophilia, we studied the records of 453 women with pregnancy-associated complications. In 55 women, intrauterine fetal death (fetus mortus in utero, FMU) after 20 weeks ...
DeSancho Maria Teresa - - 2010
Carriers of Factor V Leiden and prothrombin G20210A gene mutations have an increased risk of developing thromboembolic events and adverse outcomes of pregnancy. The objective of the present study was to identify risk factors which may predispose carriers of Factor V Leiden and/or prothrombin G20210A gene mutations to develop thromboembolic ...
Miti? Gorana - - 2010
INTRODUCTION: The optimal treatment of pregnancy associated VTE (venous thromboembolism) has not been established yet. OBJECTIVE: The assessment of the efficacy and safety of low molecular weight heparin (LMWH) nadroparin and unfractionated heparin (UFH) used for the treatment of pregnancy and puerperium related VTE. Primary study goals were to analyze ...
Sedano-Balbás Sara - - 2010
Activated Protein C Resistance (APCR), a poor anticoagulant response of APC in haemostasis, is the commonest heritable thrombophilia. Adverse outcomes during pregnancy have been linked to APCR. This study determined the frequency of APCR, factor V gene known and novel SNPs and adverse outcomes in a group of pregnant women. ...
Che Yaakob Che Anuar - - 2010
Thromboembolic complications are much higher in pregnancy due to procoagulant changes. Heparin does not cross the placenta and the use of unfractionated heparin (UFH) is the current established practice in prophylaxis and treatment for thromboembolism in pregnancy. To compare the effectiveness of anticoagulant therapies for the treatment of deep vein ...
Silver Robert M RM Departments of Obstetrics and Gynecology at the University of Alabama at Birmingham, Birmingham, Alabama, USA. - - 2010
To estimate whether maternal carriage of the prothrombin gene G20210A mutation is associated with pregnancy loss, preeclampsia, placental abruption, or small for gestational age (SGA) neonates in a low-risk, prospective cohort. This was a secondary analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development factor ...
Oberkersch Roxana - - 2010
INTRODUCTION: Low-molecular-weight heparin is used clinically for the prevention of pregnancy complications associated with prothrombotic disorders, particularly anti-phospholipid syndrome. Nevertheless, recent studies have suggested that heparin may exert direct effects on the placental trophoblast, independently of its anticoagulant activity. In addition, heparin prevents complement activation in vivo and protects mice ...
Allison Jana L - - 2009
PURPOSE OF REVIEW: First trimester pregnancy loss affects up to 15% of clinically recognized pregnancies. Whereas most couples will proceed to have successful subsequent pregnancies, 2-4% will suffer recurrent losses, often with no identifiable cause. In fact, up to 40-50% of patients suffering recurrent pregnancy loss (RPL) will have no ...
Hanprasertpong Tharangrut - - 2009
Cerebral venous sinus thrombosis, an unusual presentation of antiphospholipid syndrome, is a rare condition in pregnancy, particularly in the first trimester. The authors of this case report present the case of a 20-year-old woman with sudden onset of headaches and hemiparesis in the first trimester of pregnancy. She underwent a ...
Mantha S S Division of Hematology-Oncology, Lahey Clinic, Burlington, MA, - - 2010
The management of recurrent pregnancy loss is uncertain. Some cohort studies have identified an association between inherited thrombophilias and recurrent or late non-recurrent pregnancy loss, which has prompted investigators to evaluate the benefit of low molecular weight heparin (LWMH) to achieve live birth. A similar benefit for LMWH has also ...
Tranquilli Andrea Luigi - - 2010
Carrier status of the fetus for factor V polymorphism or double homozygosity for mutant alleles of the PAI-1 4 G/4 G and MTHFR T677 T polymorphisms must be considered risk factors for intrauterine fetal death. The clinical implications of these data need to be addressed in a prospective study to ...
Bramham K - - 2010
Women with antiphospholipid syndrome (APS) may have diverse pregnancy outcomes. The objective of this study was to evaluate pregnancy outcome in women with APS according to their clinical phenotype, i.e. thrombotic and obstetric APS. Eighty-three pregnancies in 67 women with APS were included in the study, including 21 with recurrent ...
Bourjeily Ghada - - 2010
Pulmonary embolism (PE) is the leading cause of maternal mortality in the developed world. Mortality from PE in pregnancy might be related to challenges in targeting the right population for prevention, ensuring that diagnosis is suspected and adequately investigated, and initiating timely and best possible treatment of this disease. Pregnancy ...
Quinn John - - 2009
The use of standard dose low molecular weight heparin (LMWH) to anticoagulate women with mechanical valves in pregnancy is associated with morbidity and mortality. We conducted a prospective audit of the use of adjusted dose high intensity LMWH in 12 pregnancies in 11 women with prosthetic heart valves. LMWH +/- ...
Dempfle Carl-Erik - - 2009
Monitoring of anti-factor Xa activity is often performed during treatment with low-molecular-weight heparins (LMWHs) in pregnancy because the anticoagulant effect may decrease as pregnancy progresses, but assays for anti-factor Xa activity are unavailable in many clinical institutions caring for pregnant women. Heptest-STAT is a new clotting assay for monitoring of ...
Ozer Orhan - - 2010
The incidence of prosthetic valve thrombosis (PVT), which is a life-threatening complication, increased during pregnancy because of the hypercoagulable state. Despite adequate anticoagulation, the incidence of PVT has been estimated as 4% to 14% during pregnancy. Prosthetic valve thrombosis occurring during pregnancy requires urgent therapy including fibrinolytic therapy, valve replacement, ...
Carnero-Alcázar Manuel - - 2010
Pregnant women with a mechanical heart prosthesis are at a higher risk of thromboembolic complications. The optimal anticoagulation strategy in this setting remains unclear. When prosthesis thrombosis happens and cardiac surgery must be performed, the risk of fetal mortality is high. Special attention must be paid to improve the placental ...
Ferroni Patrizia - - 2010
BACKGROUND: A condition of maternal thrombophilia, either inherited or acquired, can compromise the success of implantation and foetal survival. METHODS: Malfunctions in protein C pathway were evaluated using a novel assay [HemosIL ThromboPath (ThP)] in a case-control study of 172 women with a history of recurrent miscarriage or infertility and ...
Cochery-Nouvellon Eva - - 2009
The endothelial protein C receptor (EPCR) is expressed by trophoblast cells. Mid-gestation pregnancy loss is described in animals with a haemochorial placenta lacking EPCR. The A6936G allele of the EPCR gene (PROCR) may be associated with lower EPCR densities on trophoblasts, but data are lacking for its effect on the ...
Verspyck Eric - - 2010
OBJECTIVE: We sought to evaluate whether testing for hereditary thrombophilia alone or in combination with second-trimester uterine artery Doppler (UAD) is useful in predicting recurrent complications in patients with previous preeclampsia, placental abruption, or stillbirth. STUDY DESIGN: Between 2001 and 2005, 110 consecutive women were included in the study and ...
Yinon Yoav - - 2009
There are a number of different anticoagulation options for pregnant women with mechanical heart valves. The purpose of this study was to examine maternal thromboembolic complications in women with mechanical valves treated with low-molecular weight heparin (LMWH) throughout pregnancy. This was a substudy of a larger prospective cohort study of ...
Bianca Sebastiano - - 2010
Our study does not support the reported association between APOE and recurrent pregnancy loss (RPL) than the clinical management of these patients should not be influenced by the presence or not of APO E polymorphisms.
Dao Vi - - 2009
PURPOSE OF REVIEW: Placenta-mediated pregnancy complications are relatively common and are associated with significant morbidity and mortality. Although anticoagulants are increasingly being used to prevent these complications, the evidence supporting their use is limited. This article will focus on reviewing the current evidence base for the use of anticoagulants to ...
Jeon Gyun-Ho - - 2009
OBJECTIVE: To investigate recurrent miscarriages in Koreans in terms of causative factors and the prognosis for subsequent successful pregnancies in primary and secondary recurrent miscarriages cases. STUDY DESIGN: The study retrospectively examined the clinical records of 222 recurrent miscarriage cases that were presented at the Department of Obstetrics and Gynecology, ...
Martineau M - - 2009
Although venous thromboembolism is a preventable and treatable condition, it remains the most common cause of direct maternal death in the UK, with a four-fold increased incidence compared to that of the non-pregnant population. The risk of VTE is apparent from early pregnancy and maximal immediately postpartum. Increasing rates of ...
Hossain Nazli - - 2009
Anticoagulant therapy has been used extensively for the prevention of recurrent pregnancy losses, and other placenta mediated complications, including prevention of preeclampsia and fetal growth restriction. While heparin anticoagulation is a standard treatment for antiphospholipid antibody syndrome, it is increasingly being used in the prevention of placenta mediated complications. In ...
Clark Nathan P - - 2010
INTRODUCTION: Unfractionated heparin (UFH) does not cross the placenta and has demonstrated utility in the prevention and treatment of thrombosis during pregnancy. Limited information is available to guide initiation and monitoring of therapeutic UFH targeting an anti-Xa concentration of 0.3-0.7 u/ml during pregnancy. The objective of this study was to ...
McLintock C - - 2009
OBJECTIVE: To determine maternal and fetal outcomes in women with mechanical heart valves managed with therapeutic dose enoxaparin during pregnancy. DESIGN: Retrospective audit. SETTING: Hospital-based high-risk antenatal clinics. POPULATION: Pregnant women with mechanical heart valves attending high-risk antenatal clinics, treated with enoxaparin (1 mg/kg twice daily) during pregnancy. METHODS: Women ...
< 4 5 6 7 8 9 10 11 12 13 14 >